3 years ago

Early impact of guideline publication on angiotensin-receptor Neprilysin inhibitor use among patients hospitalized for heart failure

On 5/20/2016, U.S. professional organizations in cardiology published joint treatment guidelines recommending the use of angiotensin-receptor neprilysin inhibitor (ARNI) for eligible patients with heart failure with reduced ejection fraction (HFrEF). Objective Using data from the Get With The Guidelines-Heart Failure registry, we evaluated the early impact of this update on temporal trends in ARNI prescription. Methods We analyzed patients with HFrEF who were eligible for ARNI prescription (EF ≤40%, no contraindications) and hospitalized from 2/20/2016 through 8/19/2016—allowing for 13weeks before and after guideline publication. We quantified trends in ARNI use associated with guidelines publication with an interrupted time-series design using logistic regression and accounting for correlations within hospitals using general estimating equation methods. Results Of 7200 eligible patient hospitalizations, 51.9% were discharged in the period directly preceding publication of the guidelines and 48.1% were discharged after. Odds ratios of ARNI prescription at discharge were significantly higher in the post-guideline period compared with the pre-guideline period in adjusted models (Adjusted OR 1.29; 95% CI 1.06–1.57; P =.01). However, there was no significant interaction between observed and expected ARNI use after guideline publication (pinteraction =0.14). Results were consistent using a 6-month before and after time-frame. Conclusions and relevance The model suggested a small increase in ARNI use in heart failure patients being discharged from the hospital immediately after guideline release. However, the publication of national guidelines recommending ARNI use seemed to have little influence on the adoption of this evidence-based medication in the first 3 to 6months.

Publisher URL: www.sciencedirect.com/science

DOI: S0002870318300358

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.